Ascites Market Size in the 7MM is expected to grow at a significant CAGR by 2034, estimates DelveInsight

DelveInsight's "Ascites Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Ascites, historical and forecasted epidemiology as well as the Ascites market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Unlock detailed insights into the Ascites Market by downloading the comprehensive report from DelveInsight @ Ascites Treatment Market Size- https://www.delveinsight.com/sample-request/ascites-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Ascites Market Report
• On February 19, 2026, Yale University announced a trial to explore the acute and 14-day effects of empagliflozin on natriuresis and total body water in patients with cirrhosis and ascites. We will additionally investigate its effect on neurohumoral activation and renal hemodynamics.
• Among the 7MM, the US accounted for the highest number of ascites cases due to cirrhosis, with more than 152,000 cases in 2023. These numbers are anticipated to increase during the forecast period (2024-2034).
• Among the number of ascites cases caused by malignancies, breast cancer accounted for the highest number, with nearly 13,000 cases, followed by colorectal cancer in the US in 2023.
• Among the severity-specific cases, Grade II and III accounted for nearly 125,000 cases in the US in 2023.
• Among the EU4 and the UK, Germany accounted for the highest number of cases, followed by the UK, while Spain occupied the bottom of the ladder.
• The leading Ascites Companies such as Grifols Therapeutics LLC, Sanofi, Regeneron Pharmaceuticals, Sequana Medical N.V, Protgen Ltd, Healthgen Biotechnology Corp, Sichuan Clover Biopharmaceuticals Inc, Movetis, BioVie Inc., Ocelot Bio Inc, Novartis, and others.
• Promising Ascites Therapies such as Recombinant Human Serum Albumin, M701, paracentesis, OrsHSA, VS-01, Ambrisentan, Terlipressin, and others.

Gain a competitive edge in the Ascites Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Ascites Treatment Drugs- https://www.delveinsight.com/sample-request/ascites-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Ascites Epidemiology Segmentation in the 7MM
• Number of Ascites Cases by Malignancies
• Number of Ascites Cases due to Cirrhosis
• Severity-specific Cases of Ascites due to Cirrhosis
• Refractory Ascites Patients with Cirrhosis

Ascites Treatment Market Landscape
The treatment landscape of ascites due to cirrhosis include diuretics, paracentesis, insertion of a transjugular intrahepatic portosystemic shunt (TIPS), as well as managing complications to ascites such as spontaneous bacterial peritonitis (SBP). Mild and moderate ascites due to liver cirrhosis can be treated with dietary sodium restriction, treatment of the underlying disorder, fluid restriction, use of diuretics, and use of therapeutic paracentesis.

Ascites Emerging Drugs
• PHIN-214: PharmaIN
PharmaIN has advanced PHIN-214, a novel compound being developed for treating refractory ascites due to advanced liver cirrhosis, into a US Phase Ib clinical trial in cirrhotic patients. The therapeutic approach of PHIN-214 therapy is to shut down the RAAS signaling pathway, thereby halting the retention of excess salt and water by the kidneys and ending ascites fluid production.

• OCE-205: Ocelot Bio
Ocelot Bio is developing OCE-205, an investigational therapy to transform the treatment of end-stage liver disease. The company is also developing OCE-205 for the treatment of ascites, a complication of ESLD-induced portal hypertension that leads to the accumulation of fluid in the peritoneal cavity. Currently, the company is conducting a Phase II multi-center, randomized, placebo-controlled, double-blind, adaptive dose-ranging study to assess the safety and efficacy of intravenous OCE-205 in adults diagnosed with cirrhosis with ascites who have developed hepatorenal syndrome-acute kidney injury, and a Phase I clinical trial of ascites.

Discover key developments and opportunities in the Ascites Market. Click here to learn more from DelveInsight's latest report @ Ascites Market Size- https://www.delveinsight.com/sample-request/ascites-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Ascites Drugs Market
The Ascites market for drugs targeting ascites is notably constrained. While certain treatments provide symptomatic relief, there is a significant lack of approved drugs addressing the condition's underlying causes. This scarcity of targeted treatments reflects a major challenge in effectively managing the diverse manifestations of ascites, indicating a substantial need for innovative solutions and advancements in drug development for more comprehensive care.

Ascites Market Outlook
Sodium restriction and diuretics are the mainstays of treatment for patients with ascites due to portal hypertension, but patients with low Serum Ascites Albumin Gradient (SAAG) (less than 1.1 g/dL) ascites do not respond well to these measures, except those with nephrotic syndrome. Tolvaptan, a novel aquaporin modulator, was made available in Japan in 2013 for the treatment of patients with refractory ascites due to cirrhosis. However, it is not approved in Japan for the treatment of ascites.

Download DelveInsight's Ascites Market report today and stay ahead in this rapidly evolving field. @ Ascites Clinical Trials- https://www.delveinsight.com/sample-request/ascites-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Ascites Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Ascites Companies- as Grifols Therapeutics LLC, Sanofi, Regeneron Pharmaceuticals, Sequana Medical N.V, Protgen Ltd, Healthgen Biotechnology Corp, Sichuan Clover Biopharmaceuticals Inc, Movetis, BioVie Inc., Ocelot Bio Inc, Novartis, and others.
• Ascites Therapies- Recombinant Human Serum Albumin, M701, paracentesis, OrsHSA, VS-01, Ambrisentan, Terlipressin, and others.
• Ascites Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Ascites Unmet Needs, KOL's views, Analyst's views, Ascites Market Access and Reimbursement

Download the report to understand which factors are driving Ascites Market Trends @ Ascites Market Trends- https://www.delveinsight.com/sample-request/ascites-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Ascites Market Report Introduction
3. Executive Summary
4. Ascites Market Overview at a Glance
5 Key Events
6 Ascites Epidemiology and Market Forecast Methodology
7 Ascites Disease Background and Overview
8 Ascites Epidemiology and Patient Population
9 Patient Journey
10 Ascites Emerging Therapies
11 Ascites: Seven Major Market Analysis
12 Ascites Unmet Needs
13 Ascites SWOT Analysis
14 KOL Views
15 Ascites Market Access and Reimbursement
16 Appendix
17 DelveInsight Capabilities
18 Disclaimer
19 About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.